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We undertook a qualitative e-mail survey of federally-funded principal investigators of their views of the US 
human subjects protection system, intended to identify the range of investigator attitudes. This was an 
exploratory study with a 14% response rate. Twenty-eight principal investigators responded; their comments 
were analyzed to show underlying themes, which are here presented along with supporting quotations.  
There was consensus that it is important to protect human subjects from research abuse, but disagreement over 
how well the IRB system is functioning. Some researchers felt that the system is effective and serves its purpose 
well. Of those who support the system, some endorse its methods, purpose, and daily functioning, as they 
experience it, without reservation. Others, while expressing some frustration, feel that the purpose is important 
and their local IRB does its best to make a difficult system work well. 
Those investigators who were more harshly critical commented on multiple flaws in the system, including (1) 
consent forms that are inappropriate and incomprehensible, (2) an emphasis on minutiae, and (3) concern with 
protecting the institution more than research subjects. Respondents told us that the IRB system is a particular 
burden for research in neurology, emergency medical conditions, repositories, and social sciences in general; a 
more comprehensive study might identify other problematic areas. Significant concern was expressed about the 
cost, inefficiency, and irrationality of IRB review. The IRB system works well for some researchers, but our results 
indicate that other investigators feel the costs outweigh the benefits.  
Key words: Ethics Committees, Research, Questionnaires, Attitude 
INTRODUCTION 
The human subjects protection system is 
ever-enlarging yet its quality and efficiency are cast in 
doubt by experts, [1] review bodies, [2] and field- or 
discipline-specific committees. [3] In a complex system 
with multiple stakeholders, one important source of 
insight is with those who are regulated—the principal 
investigators. The views of investigators are therefore 
important in understanding the system as it functions 
today. 
Previous work suggests that the opinions of 
investigators toward the IRB system are mixed. An 
informal survey of members of several social science 
organizations conducted in 2000 drew mixed results. 
Some of the researchers who were polled reported 
excellent rapport with their local IRBs; others were 
frustrated by a system that delayed and obstructed 
their research. [3] Borris and Moss studied the views of 
a group consisting primarily of federally-funded 
principal investigators; they identified significant 
problems with the system. [4] Investigators whose 
research requires data collection in more than one 
location have been especially vocal about the 
shortcomings of the IRB system. [5-7] 
We undertook a study of researchers’ attitudes 
toward the IRB system, using a confidential e-mail 
questionnaire format to encourage candid responses. 
We limited our sample to investigators with current 
NIH funding in human subjects research. We 
recognized that this unfunded work could not attempt 
to paint a comprehensive picture of researchers’ 
attitudes and experiences; our more modest goal was 
exploratory, to gather the range of attitudes from a 
small sample of people with in-depth knowledge of 
the system. 
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METHODS  
Surveys were sent via e-mail in two phases in 
2003, using NIH-funded principal investigators listed 
in the CRISP database whose project abstracts 
indicated that they used human subjects. The pilot 
phase used a single e-mail solicitation only, including a 
six item questionnaire. This was sent to 34 
investigators; four had invalid e-mail addresses, and 
two responses were received, for a response rate of 7%. 
The second phase survey was sent to 193 investigators 
who were NIH-funded to do research in human 
subjects in 2003. This phase included an e-mail alerting 
potential subjects to the study, an e-mail containing the 
survey, and two follow-ups for those who did not 
respond to the initial solicitation.  Thirteen of our 
subjects did not have valid e-mail addresses; of the 
remaining 180, valid responses were received from 26. 
We combined respondents from the first and second 
phases, giving us a final sample size of 28, which is 
adequate for the purposes of qualitative analysis. 
Because this was an exploratory study, we asked 
open-ended questions and analyzed the responses 
qualitatively. The project was approved by the Baylor 
College of Medicine Institutional Review Board. 
The final survey included these items: 
1. What has been your experience with the human 
subjects protection system in general? What do you 
like? What would you change? 
2. What has been your experience with the 
informed consent process with potential subjects? Is 
there anything you would change? 
3. Do you feel your IRB does its job well? If so, 
what helps you the most? If not, how could it improve? 
4. Do you feel that your IRB usually understands 
your protocols adequately? 
5. Have you ever served on an IRB? 
6. What other thoughts do you have on informed 
consent and the human subjects protection system? 
RESULTS 
I. Positive comments 
A. Toward the system  
Some respondents emphasized their conviction 
that the human subjects protection system is an 
essential safeguard in clinical research. Respondents 
identified several significant benefits of the overall 
system, including its function as a safeguard against 
overoptimistic investigators (subject 6), protecting 
subjects against both nonphysical and physical harms 
(subject 6), the promotion of “social justice” (subject 6), 
and the provision of online ethics training by the NIH 
(subject 22).  
I think that the informed consent process is an 
essential element of both research and treatment. 
Risks occur in many situations that are not 
commonly perceived as such and individuals 
deserve protection. (subject 6) 
Another respondent noted that self-interest is 
also a motivation:  
My experience has been good to excellent 
overall. The time I have to spend on consent 
forms and IRB approval is bothersome at times 
but I gladly do it knowing that this system 
protects every researcher. I don't want my 
research shut down because some other 
researcher was sloppy and a subject was harmed. 
The IRB system is the only protection I have 
against that. (subject 15) 
B. Toward individual IRBs 
Individual IRBs were lauded for taking their 
work seriously (subjects 6, 13, 18, 20, and 23), for being 
sensible (subject 24), and for having a service 
orientation, including frequent meetings (subject 8), 
prompt responses (subject 6), bringing in outside 
expertise when appropriate (subject 6), and providing 
individual help and feedback (subjects 8, 11, 14, 15, 
and 16). Some respondents praised their IRB for 
excellence in helping researchers within a set of 
constraints that are challenging: 
[Our] IRB has been good to work with, and I 
don't have the same horror stories that I've heard 
from others. They labor under the same 
antedeluvian mindset that has been imposed on 
everyone, but have accommodated to it in a way 
that is helpful to researchers in general. Most 
important, our IRB has avoided the pitfall of 
rewriting protocols (subject 8).  
II. Negative comments 
A. The system as a whole 
 Not all of our subjects felt that the human 
subjects protection system works adequately.  
Overall, I find the people working in IRB offices 
to be trying very hard to keep a sane approach in 
what is rapidly deteriorating into an very insane 
process. The constraints placed upon 
investigators and indeed research subjects by 
OHPR and so-called ethicists approaches the 
absurd. I am both a PI and have participated in 
clinical trials [as a subject]. Getting protocols 
approved gets worse each year because you have 
to document more and more and more USELESS 
stuff. For most of my work I receive coded 
samples devoid of patient identifiers, yet I have 
to fill in all sorts of crap and REPEAT OVER 
AND OVER AND OVER AGAIN that I couldn't 
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track down these subjects if i tried. Examples of 
this absurdity include: mandating IRB approval 
for a collaborator to look at the viral sequences 
from patients samples that were devoid of all 
identifiers. He may be good but I doubt he could 
look at someone and figure out who they were 
by the sequence of their virus. (subject 27) 
B. Consent forms 
Informed consent, by which our subjects mean 
the consent forms that are the focus of much IRB effort, 
was treated with widespread derision, with 15 out of 
28 of our subjects providing criticisms such as 
“unlikely to be read,” or “incomprehensible.” (subjects 
1, 4, 8, 10, 11, 12, 14, 15, 16, 17, 24, 25, 26, 27, 28) 
Excessive length and detail were commonly cited, 
resulting in reduced understanding (subject 11) and 
potentially reduced enrollment. (subjects 14, 15, 16, 17) 
Researchers were troubled by requirements to mention 
the risk of death even in minimal risk procedures 
(subjects 4, 17, 25) and felt that inappropriate language, 
such as a paragraph on the risk of death in a minimal 
risk procedure, was inflammatory and unduly 
frightening. (subjects 4, 17, 25)  
Most informed consents include FAR TOO 
MUCH INFORMATION and the average person 
doesn't understand what is in them. They don't 
inform, at best they bore and confuse. Informed 
consents have become "legal" documents to 
protect the institutions from OHPR and have 
little to do with informing subjects let alone 
protecting them. (subject 27) 
C. IRBs 
IRBs were often portrayed as slow or 
cumbersome. (subjects 1, 4, 7, 12, 14, 16, 28) Caution 
was reflected in the refusal of a Department of Health 
IRB that refused to approve smoking-related research 
because it was “too politically hot.” IRBs were seen by 
some as not competent in the area under review 
(subject 4), not understanding the protocols (subject 4) 
or the analytic methods (subject 27) submitted.  
Some IRBs were seen as applying federal 
regulations and their own local custom in arbitrary 
and even irrational ways. One IRB required that the 
informed consent form be written at the sixth grade 
reading level even when the subjects are college 
students. (subject 19) Another respondent commented,  
I believe that most subjects skim through the 
incredibly long informed consents, believing that 
most of it is simply bureaucracy. They often are 
most puzzled by statements such as denial that 
an institution will pay for medical costs if they 
are injured in a study, when their participation 
simply includes filling out questionnaires. 
(subject 10) 
Two respondents spontaneously mentioned fear 
of IRBs.  
There is…quite some show of 'muscle' and if a 
member has a score to settle with an investigator, 
woe to the whole study. I have seen when 
investigators are frustrated but they dare not 
speak out lest the committees sit on their studies 
for ever (with a what-can-you-do attitude). You 
should see they way the letters to IRBs are full 
of 'pleading' words, and this is characteristic of 
both the local and the US IRBs I have had the 
misfortune of working with in other studies! 
(subject 28) 
A final comment: All of our emails may be 
monitored, and although I have nothing to say 
that I would not share with any official of [my 
institution], and email is convenient, I wonder if 
this is the wisest way to conduct this survey? 
(subject 10) 
D. Protection . . . for whom 
Seven subjects, one quarter of our sample, 
commented that IRBs do not seem to have protecting 
subjects as their highest priority. (subjects 8, 9, 10, 12, 
14, 27, 28) 
Many IRB members are out more to protect 
themselves (from possible future lawsuits) than 
the hullabaloo about protecting study subjects. 
Many make decisions that harm clients in the 
long run without caring at all, as long as THEY 
feel safe. (subject 28) 
Informed consent has clearly transmogrified 
from protection of subjects to protection of the 
institution. We are required to use language that 
is incomprehensible to most research subjects (I 
do street based work in STD/HIV and many of 
our clients are not fluent readers, so the problem 
is greater for me and my colleagues). This 
absurdity has recently been compounded by 
HIPAA, and the extra pages that clients must 
now wade through. In short, the informed 
consent process has become a travesty. (subject 
8) 
E. Specific areas of research  
 The most impassioned comments were made by 
investigators who believe that entire lines of research 
are made difficult or impossible by the human subjects 
protection system. (subjects 1, 9). Respondents 
identified four specific lines of research that are so 
burdened.  
1. Neurology 
A researcher who works in Neurology pointed to 
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the difficulties posed by the human subjects protection 
system and raised a corollary concern, that the system 
discourages young researchers from entering careers 
in human research: 
If parents of children dying of some of the 
diseases we encounter in neurology understood 
how much more cumbersome and expensive 
research is as the result of this system, the system 
would be in big trouble. Even worse if they 
realized how these problems conspire to dampen 
enthusiasm of young people who might 
otherwise have gone into clinical/translational 
research. (subject 2) 
2. Social science research 
Three respondents commented that the system 
(both the regulations and their application by 
individual IRBs) seems to them to work badly for 
social science research. (subjects 10, 11, 26) One 
respondent, who had served as chair of an IRB, 
commented: 
What I would like to see changed is the federal 
law/policy that was developed specifically for 
biomedical research. It needs to be adapted for 
social science research. . . . For instance, it makes 
no sense to mention alternative procedures when 
conducting a lab experiment or field survey. … 
Some common sense could be applied to develop 
an appropriate parallel set of guidelines to fit the 
needs of social science. (subject 11) 
3. Urgent or emergent medical conditions 
Obtaining informed consent according to usual 
standards was a particular problem in research in 
emergency medical conditions (subjects 14, 16): 
I am involved in acute stroke clinical trials, and 
informed consent with a confused patient and 
family in the ER under a very tight time limit is 
very difficult. (subject 14) 
4. Repository research  
A repository or data bank is a collection of 
medical information, tissue or blood samples, or other 
information from many individuals. 
The constraints on repository material are a 
major set back in science and I hope all those at 
OHPR and the ethicists die of diseases that we 
could have made significant progress on if we 
had these valuable research. USE OF THESE 
SAMPLES IN NO CONCEIVABLE way harms 
the study subjects. It is a bureaucratic legalistic 
impediment to research that only HURTS people 
and protects no one. (subject 27) 
F. A system under stress 
Some of our subjects granted that it is essential to 
protect human subjects yet questioned the viability of 
the current system. One respondent, a former chair of 
an IRB, commented: 
We've reached a point . . . where the logic of 
increasing improbability holds sway. If 
something could happen, it might happen, or 
perhaps it will happen, and we must defend 
against it. The work of the IRB has become the 
intellectual (jesuitical? talmudic?) exercise of 
trying to see what could go wrong and taking 
steps to prevent it, whatever the probability and 
whatever the cost. This is the same logic that 
drives airport security. To stave off an event with 
nanoprobability but enormous potential impact, 
we have to do everything to everybody, and 
such an imperative has an inescapable logic. You 
begin at Point A, and have logical justification 
for each step along the way to Z, but the 
situation you end up in, at Z, is ludicrous. . . . The 
system is clearly in a downward spiral, as the . . . 
addition of HIPAA requirements demonstrates. 
This involution takes us deeper into a 
bureaucratic morass, from which there is no 
visible exit strategy at the moment. I think all of 
us will just have to wait until it becomes 
apparent that useful research on human subjects 
cannot be performed, and there is a sea change in 
the way we approach the issue of protecting 
people from us. (subject 8) 
DISCUSSION 
All of our subjects explicitly or implicitly 
recognized the importance of treating human subjects 
appropriately. All of our subjects have worked with 
the human subjects protection system, and forty 
percent, including two respondents whose comments 
were entirely negative, were present or former 
members of IRBs.  
Where investigators perceive problems, it is 
important to distinguish flawed implementation of 
regulations by the local IRB from problems inherent in 
the IRB system or in the governing regulations 
themselves. Some of our respondents complained, 
perhaps appropriately; others were happy to point out 
ways in which their IRB met its ethical obligations in a 
timely, courteous, and efficient manner.  
This was an exploratory study with a low 
response rate, which imposes significant limits on the 
conclusions we can draw. These data do not support 
quantitative inferences. Our results show clearly that 
researchers range from very satisfied to extremely 
dissatisfied with the IRB system, but we cannot tell 
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how these attitudes are distributed across the many 
thousands of investigators doing human subject 
research today.  
Sometimes there is tension between protecting 
human subjects and permitting research to go forward. 
Our system correctly prohibits research that sacrifices 
the interests of subjects even if society might benefit. 
[8] Sometimes, however, the risks (to the individual) 
and benefits (for society) are not easy to compare; this 
is most apparent in our subjects’ discussions of 
research in neurology, using repository material, in the 
social sciences, and in emergency and neurological 
medical conditions. We did not intend a 
comprehensive study of the impact of the IRB system 
on different areas of research, and did not inquire as to 
the field of research of our respondents, learning this 
information only when it was volunteered. We suspect 
that a larger survey would have identified more areas 
in which the IRB system causes severe difficulties, as 
well as other research methodologies that are 
particularly burdened (the problems with IRB review 
of multicenter research are already well documented). 
The current exception for research in emergencies 
works, at least for subject 14, well enough to make 
research in acute stroke possible, but still imposes a 
substantial burden. In some circumstances, time spent 
obtaining informed consent of any kind (for research 
or for clinical treatment) directly reduces the time 
available for prompt and effective intervention.  
Social science is a particularly hard case. IRBs 
work hard to protect the subjects of social science 
research. It is, however, clear that some of the federal 
regulations pertaining to research were not designed 
to apply to social science research, and that some IRBs 
do not understand this type of investigation.  
The most important protection against abuse of 
human subjects is the high ethical standard of 
individual researchers. Some of our respondents 
understand that protecting human subjects is more 
than using an approved consent form. One respondent 
commented that his experience with the human 
subjects protection system has been “. . . positive but 
cumbersome. I like going through the process of being 
forced to think concretely about all possible ethical 
dilemmas associated with a project in advance.” 
(subject 4) This expresses nicely the attitude of a 
conscientious investigator for whom the protection of 
human subjects is an ideal. Many of our subjects feel 
that the bureaucratic process now in place does little to 
bring that ideal to reality. 
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